Biotechnologies to tackle the challenge of neoantigen identification.

Marion Arnaud, Margaux Duchamp, Sara Bobisse, Philippe Renaud, George Coukos, Alexandre Harari

Current opinion in biotechnology 2020 Oct

filter terms:

Among immune correlates of clinical responses, tumor-specific neoantigens took the spotlight as relevant targets for cancer immunotherapy. The implementation of pipelines for personalized cancer therapy remains challenging due to the privacy, that is patient-specificity, of neoantigens and the low-frequency of neoantigen-specific T cells in blood and tumor samples. To overcome these obstacles, recent developments in the field of biotechnology have allowed the multiplexed identification of neoepitope-specific T cells. This review addresses the pros and cons of conventional neoantigen screening methodologies and highlights the current as well as the prospective biotechnological opportunities in the field. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Citation

Marion Arnaud, Margaux Duchamp, Sara Bobisse, Philippe Renaud, George Coukos, Alexandre Harari. Biotechnologies to tackle the challenge of neoantigen identification. Current opinion in biotechnology. 2020 Oct;65:52-59